1. Home
  2. CVR vs BIVI Comparison

CVR vs BIVI Comparison

Compare CVR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Rivet & Machine Co.

CVR

Chicago Rivet & Machine Co.

N/A

Current Price

$12.23

Market Cap

10.4M

Sector

Industrials

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.42

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVR
BIVI
Founded
1920
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
14.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CVR
BIVI
Price
$12.23
$1.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1K
60.7K
Earning Date
11-07-2025
11-10-2025
Dividend Yield
0.84%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,008,045.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.15
$1.25
52 Week High
$17.26
$27.00

Technical Indicators

Market Signals
Indicator
CVR
BIVI
Relative Strength Index (RSI) 78.71 42.45
Support Level $10.01 $1.45
Resistance Level $11.00 $1.63
Average True Range (ATR) 0.61 0.09
MACD 0.54 0.02
Stochastic Oscillator 94.13 35.90

Price Performance

Historical Comparison
CVR
BIVI

About CVR Chicago Rivet & Machine Co.

Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: